Drug
MK-5172A clinical trials
Also written MK-5172A.
- studies test it
- 4
- open now
- 0
- in phase 3
- 1
- first study started
- 2014
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 2
- Phase 3
- 1
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses MK-5172A is read from its arms, and is right about nine times in ten.
Testing it · 4
- Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)CompletedPhase 2Merck Sharp & Dohme LLCNCT03379506Written as EBR/GZR FDC Tablet
- Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096)CompletedPhase 4Merck Sharp & Dohme LLCNCT03111108Written as EBR/GZR (50 mg/100 mg) FDC
- Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)CompletedPhase 2/3Merck Sharp & Dohme LLCNCT02115321Written as MK-5172A
- Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)WithdrawnPhase 4Merck Sharp & Dohme LLCNCT03143998Written as MK-5172A